BJMO - volume 14, issue 1, january 2020
P. Specenier MD, PhD, E. van Gogh MD
(BELG J MED ONCOL 2020;14(1):8–12)
Read moreBJMO - volume 13, issue 8, december 2019
P. Specenier MD, PhD
During the 2019 annual meeting of the European Society for Medical Oncology (ESMO) the most recent advances in recurrent/metastatic (R/M) and locoregionally advanced (LA) squamous cell carcinoma of the head and neck (HNSCC) as well as nasopharyngeal carcinoma were discussed. In R/M HNSCC the safety and efficacy of monalizumab alone and in combination with cetuximab was assessed and the ELAN trials tried to assess the management of elderly HNSCC patients. In LA HNSCC the efficacy of Debio 1143 in combination with chemoradiotherapy as well as the dominance of cisplatin over cetuximab in association with radiotherapy were studied. In nasopharyngeal carcinoma, results were presented on the benefit of radiotherapy to chemotherapy with cisplatin and fluorouracil. Finally, Bossi et al. demonstrated that in non-endemic countries, patients with nasopharyngeal carcinoma have the same survival figures and prognostic factors as patients in endemic areas.
Read moreBJMO - volume 13, issue 6, october 2019
P. Specenier MD, PhD
Overview of Belgian reimbursement news
(BELG J MED ONCOL 2019;13(6):266–267)
Read moreBJMO - volume 13, issue 5, august 2019
P. Specenier MD, PhD
ASCO 2019 hosted several important presentations on Squamous Cell Carcinoma of the Head and Neck (HNSCC). Data on early stage and locally advanced HNSCC as well as recurrent/metastatic HNSCC were discussed.
Read moreBJMO - volume 13, issue 4, june 2019
P. Specenier MD, PhD, A. Waeytens PhD
Overview of Belgian reimbursement news
(BELG J MED ONCOL 2019;13(4):150–151)
Read moreBJMO - volume 13, issue 1, february 2019
P. Specenier MD, PhD
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J MED ONCOL 2019;13(1):34)
Read moreBJMO - volume 12, issue 8, december 2018
P. Specenier MD, PhD
The 2018 annual meeting of the European Society for Medical Oncology (ESMO) turned out to be a grand cru for head and neck cancer, with two abstracts in this disease entity presented during the presidential sessions of the meeting. These two presentations, one on the use of immune checkpoint inhibition in the frontline treatment of recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) and one evaluating treatment de-escalation in low-risk, p16-positive oropharyngeal cancer, form the lion’s share of this report. In addition to this data were presented of clinical trials looking at the potential of durvalumab plus danvatirsen, M7824, tipifarnib and SD-101 in the treatment of R/M SCCHN.
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
